AbbVie Inc. (NYSE:ABBV) EVP Michael Severino sold 25,633 shares of the stock in a transaction on Friday, November 10th. The stock was sold at an average price of $94.69, for a total transaction of $2,427,188.77. Following the transaction, the executive vice president now owns 114,922 shares in the company, valued at approximately $10,881,964.18. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Shares of AbbVie Inc. (ABBV) opened at $94.75 on Wednesday. The company has a quick ratio of 1.32, a current ratio of 1.45 and a debt-to-equity ratio of 5.08. AbbVie Inc. has a 1-year low of $58.60 and a 1-year high of $98.26. The firm has a market cap of $151,852.42, a price-to-earnings ratio of 17.91, a price-to-earnings-growth ratio of 1.32 and a beta of 1.51.
AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 27th. The company reported $1.41 earnings per share for the quarter, beating analysts’ consensus estimates of $1.39 by $0.02. The firm had revenue of $7 billion during the quarter, compared to the consensus estimate of $7 billion. AbbVie had a net margin of 24.38% and a return on equity of 153.80%. The business’s revenue was up 8.8% on a year-over-year basis. During the same period in the prior year, the firm earned $1.21 EPS. equities research analysts predict that AbbVie Inc. will post 5.55 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be issued a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.00%. This is an increase from AbbVie’s previous quarterly dividend of $0.64. The ex-dividend date of this dividend is Thursday, January 11th. AbbVie’s dividend payout ratio (DPR) is presently 62.29%.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Week Herald and is the sole property of of Week Herald. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://weekherald.com/2017/11/15/michael-severino-sells-25633-shares-of-abbvie-inc-abbv-stock.html.
Several research analysts have recently commented on the stock. BidaskClub upgraded shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Zacks Investment Research lowered shares of AbbVie from a “buy” rating to a “hold” rating in a research note on Wednesday, November 1st. SunTrust Banks, Inc. restated a “buy” rating on shares of AbbVie in a research note on Monday, October 30th. Leerink Swann dropped their price target on shares of AbbVie from $108.00 to $107.00 and set an “outperform” rating on the stock in a research note on Monday, October 30th. Finally, BMO Capital Markets set a $66.00 price target on shares of AbbVie and gave the stock a “hold” rating in a research note on Friday, October 27th. Eight equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $93.68.
Large investors have recently added to or reduced their stakes in the company. Bristlecone Advisors LLC bought a new position in shares of AbbVie during the 3rd quarter worth about $113,000. Acropolis Investment Management LLC bought a new position in shares of AbbVie during the 2nd quarter worth about $106,000. Ffcm LLC lifted its holdings in shares of AbbVie by 167.2% during the 2nd quarter. Ffcm LLC now owns 1,539 shares of the company’s stock worth $111,000 after acquiring an additional 963 shares during the period. Hudock Capital Group LLC lifted its holdings in shares of AbbVie by 109.5% during the 2nd quarter. Hudock Capital Group LLC now owns 1,542 shares of the company’s stock worth $111,000 after acquiring an additional 806 shares during the period. Finally, Hershey Trust Co. bought a new position in shares of AbbVie during the 3rd quarter worth about $139,000. 68.16% of the stock is owned by institutional investors.
AbbVie Company Profile
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.